HOMOLOGY MEDICINES INC (FIXX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:FIXX • US4380831077

0.9347 USD
+0.01 (+0.77%)
At close: Mar 25, 2024
0.892 USD
-0.04 (-4.57%)
After Hours: 3/25/2024, 8:23:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall FIXX gets a fundamental rating of 2 out of 10. We evaluated FIXX against 523 industry peers in the Biotechnology industry. FIXX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FIXX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • FIXX had negative earnings in the past year.
  • FIXX had a negative operating cash flow in the past year.
  • In the past 5 years FIXX always reported negative net income.
  • In the past 5 years FIXX always reported negative operating cash flow.
FIXX Yearly Net Income VS EBIT VS OCF VS FCFFIXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • FIXX's Return On Assets of -133.57% is on the low side compared to the rest of the industry. FIXX is outperformed by 85.71% of its industry peers.
  • FIXX's Return On Equity of -154.74% is on the low side compared to the rest of the industry. FIXX is outperformed by 67.69% of its industry peers.
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROIC N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
FIXX Yearly ROA, ROE, ROICFIXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FIXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FIXX Yearly Profit, Operating, Gross MarginsFIXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • FIXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FIXX has more shares outstanding than it did 1 year ago.
  • FIXX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FIXX Yearly Shares OutstandingFIXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
FIXX Yearly Total Debt VS Total AssetsFIXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

  • FIXX has an Altman-Z score of -8.72. This is a bad value and indicates that FIXX is not financially healthy and even has some risk of bankruptcy.
  • FIXX has a worse Altman-Z score (-8.72) than 75.00% of its industry peers.
  • There is no outstanding debt for FIXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.72
ROIC/WACCN/A
WACC9.71%
FIXX Yearly LT Debt VS Equity VS FCFFIXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

  • FIXX has a Current Ratio of 7.25. This indicates that FIXX is financially healthy and has no problem in meeting its short term obligations.
  • FIXX's Current ratio of 7.25 is fine compared to the rest of the industry. FIXX outperforms 69.56% of its industry peers.
  • FIXX has a Quick Ratio of 7.25. This indicates that FIXX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.25, FIXX is in the better half of the industry, outperforming 69.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.25
Quick Ratio 7.25
FIXX Yearly Current Assets VS Current LiabilitesFIXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for FIXX have decreased by -3.16% in the last year.
  • The Revenue for FIXX has decreased by -64.06% in the past year. This is quite bad
  • The Revenue for FIXX have been decreasing by -26.31% on average. This is quite bad
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.92% on average over the next years. This is quite good.
  • FIXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.76% yearly.
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FIXX Yearly Revenue VS EstimatesFIXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
FIXX Yearly EPS VS EstimatesFIXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FIXX. In the last year negative earnings were reported.
  • Also next year FIXX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FIXX Price Earnings VS Forward Price EarningsFIXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FIXX Per share dataFIXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.87%
EPS Next 3Y9.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • FIXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

HOMOLOGY MEDICINES INC

NASDAQ:FIXX (3/25/2024, 8:23:28 PM)

After market: 0.892 -0.04 (-4.57%)

0.9347

+0.01 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-09
Inst Owners0.11%
Inst Owner Change0%
Ins Owners15.02%
Ins Owner Change0%
Market Cap54.23M
Revenue(TTM)1.15M
Net Income(TTM)-112.95M
Analysts43.33
Price Target1.53 (63.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.28%
Min EPS beat(2)-33.05%
Max EPS beat(2)8.5%
EPS beat(4)2
Avg EPS beat(4)-10.74%
Min EPS beat(4)-33.05%
Max EPS beat(4)8.5%
EPS beat(8)4
Avg EPS beat(8)-3.52%
EPS beat(12)8
Avg EPS beat(12)7.79%
EPS beat(16)10
Avg EPS beat(16)7.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.16
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0.02
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.45%
Cap/Sales 19.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.25
Quick Ratio 7.25
Altman-Z -8.72
F-Score2
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)56.06%
Cap/Depr(5y)112.08%
Cap/Sales(3y)22.33%
Cap/Sales(5y)302.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%
EBIT growth 1Y30.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.61%
EBIT Next 3Y32.15%
EBIT Next 5Y37.25%
FCF growth 1Y16.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.34%
OCF growth 3YN/A
OCF growth 5YN/A

HOMOLOGY MEDICINES INC / FIXX FAQ

What is the fundamental rating for FIXX stock?

ChartMill assigns a fundamental rating of 2 / 10 to FIXX.


What is the valuation status of HOMOLOGY MEDICINES INC (FIXX) stock?

ChartMill assigns a valuation rating of 0 / 10 to HOMOLOGY MEDICINES INC (FIXX). This can be considered as Overvalued.


Can you provide the profitability details for HOMOLOGY MEDICINES INC?

HOMOLOGY MEDICINES INC (FIXX) has a profitability rating of 0 / 10.


How financially healthy is HOMOLOGY MEDICINES INC?

The financial health rating of HOMOLOGY MEDICINES INC (FIXX) is 6 / 10.


What is the earnings growth outlook for HOMOLOGY MEDICINES INC?

The Earnings per Share (EPS) of HOMOLOGY MEDICINES INC (FIXX) is expected to grow by 64.09% in the next year.